Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 8 | 2019 | 411 | 2.230 |
Why?
|
| Melanoma | 6 | 2019 | 331 | 1.710 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 712 | 0.880 |
Why?
|
| Acne Vulgaris | 1 | 2022 | 24 | 0.750 |
Why?
|
| Dermatologists | 2 | 2018 | 12 | 0.750 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2022 | 12 | 0.750 |
Why?
|
| Dielectric Spectroscopy | 2 | 2019 | 3 | 0.640 |
Why?
|
| Sunscreening Agents | 5 | 2019 | 22 | 0.630 |
Why?
|
| Self-Examination | 1 | 2018 | 5 | 0.600 |
Why?
|
| Sunburn | 1 | 2018 | 12 | 0.590 |
Why?
|
| Electric Impedance | 1 | 2018 | 36 | 0.570 |
Why?
|
| Margins of Excision | 1 | 2018 | 29 | 0.570 |
Why?
|
| Mohs Surgery | 1 | 2018 | 52 | 0.550 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2018 | 66 | 0.550 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 196 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 257 | 0.480 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 771 | 0.470 |
Why?
|
| Scrotum | 1 | 2012 | 7 | 0.390 |
Why?
|
| Paget Disease, Extramammary | 1 | 2012 | 3 | 0.390 |
Why?
|
| Chordoma | 1 | 2012 | 6 | 0.390 |
Why?
|
| Exanthema | 1 | 2012 | 27 | 0.380 |
Why?
|
| Sacrum | 1 | 2012 | 27 | 0.380 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 126 | 0.350 |
Why?
|
| Skin | 3 | 2022 | 372 | 0.260 |
Why?
|
| Humans | 19 | 2023 | 63297 | 0.230 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 1083 | 0.230 |
Why?
|
| Agammaglobulinemia | 1 | 2023 | 9 | 0.210 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2023 | 10 | 0.200 |
Why?
|
| Dermatologic Agents | 1 | 2022 | 20 | 0.190 |
Why?
|
| Sebaceous Glands | 1 | 2022 | 6 | 0.190 |
Why?
|
| Psoriasis | 1 | 2022 | 55 | 0.190 |
Why?
|
| Hair Follicle | 1 | 2022 | 34 | 0.180 |
Why?
|
| Masks | 1 | 2021 | 23 | 0.180 |
Why?
|
| Sun Protection Factor | 2 | 2019 | 2 | 0.180 |
Why?
|
| Biological Products | 1 | 2022 | 94 | 0.170 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 2674 | 0.170 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 220 | 0.160 |
Why?
|
| United States | 5 | 2018 | 7828 | 0.160 |
Why?
|
| Skin Aging | 1 | 2019 | 10 | 0.160 |
Why?
|
| Marketing | 1 | 2019 | 19 | 0.160 |
Why?
|
| Consumer Behavior | 1 | 2019 | 36 | 0.160 |
Why?
|
| Patient Medication Knowledge | 1 | 2018 | 3 | 0.150 |
Why?
|
| Aged | 7 | 2018 | 14394 | 0.150 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2019 | 35 | 0.150 |
Why?
|
| Drug Labeling | 1 | 2018 | 23 | 0.150 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 66 | 0.150 |
Why?
|
| Physician Assistants | 1 | 2018 | 36 | 0.150 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 47 | 0.150 |
Why?
|
| Frozen Sections | 1 | 2018 | 10 | 0.140 |
Why?
|
| False Negative Reactions | 1 | 2018 | 41 | 0.140 |
Why?
|
| False Positive Reactions | 1 | 2018 | 78 | 0.140 |
Why?
|
| Health Personnel | 1 | 2021 | 367 | 0.140 |
Why?
|
| Nurse Practitioners | 1 | 2018 | 117 | 0.140 |
Why?
|
| Dermatology | 1 | 2018 | 74 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 201 | 0.140 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 165 | 0.140 |
Why?
|
| Drug Compounding | 1 | 2018 | 76 | 0.140 |
Why?
|
| Quality Improvement | 1 | 2021 | 441 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2016 | 10 | 0.130 |
Why?
|
| Hospital Charges | 1 | 2016 | 23 | 0.130 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 24 | 0.130 |
Why?
|
| Patient Care Bundles | 1 | 2016 | 12 | 0.130 |
Why?
|
| Safety-net Providers | 1 | 2016 | 30 | 0.130 |
Why?
|
| Disease Management | 1 | 2018 | 232 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2016 | 126 | 0.120 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1146 | 0.120 |
Why?
|
| Female | 7 | 2018 | 32791 | 0.110 |
Why?
|
| Male | 6 | 2018 | 29821 | 0.110 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 1649 | 0.110 |
Why?
|
| Adolescent | 2 | 2022 | 6238 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2012 | 13 | 0.100 |
Why?
|
| Niacinamide | 1 | 2012 | 33 | 0.100 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 32 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 96 | 0.090 |
Why?
|
| Pyridines | 1 | 2012 | 111 | 0.090 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2011 | 20 | 0.090 |
Why?
|
| Awareness | 1 | 2011 | 74 | 0.080 |
Why?
|
| Self Concept | 1 | 2011 | 111 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2011 | 217 | 0.080 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 41 | 0.070 |
Why?
|
| Time Factors | 4 | 2018 | 3761 | 0.070 |
Why?
|
| Middle Aged | 4 | 2018 | 17553 | 0.070 |
Why?
|
| Adult | 3 | 2018 | 16781 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 663 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 2571 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2011 | 503 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 1749 | 0.050 |
Why?
|
| Biological Factors | 1 | 2022 | 21 | 0.050 |
Why?
|
| Insurance Claim Review | 1 | 2022 | 76 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2019 | 8 | 0.040 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2019 | 6 | 0.040 |
Why?
|
| Protective Factors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Coffee | 1 | 2019 | 19 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2018 | 89 | 0.040 |
Why?
|
| Microscopy, Confocal | 1 | 2019 | 235 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2019 | 163 | 0.040 |
Why?
|
| Baths | 1 | 2018 | 7 | 0.040 |
Why?
|
| Aerosols | 1 | 2018 | 47 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2018 | 141 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2019 | 136 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2018 | 134 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 102 | 0.030 |
Why?
|
| Biopsy | 1 | 2019 | 444 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 205 | 0.030 |
Why?
|
| Texas | 1 | 2016 | 57 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 233 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2019 | 483 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2018 | 209 | 0.030 |
Why?
|
| Fee-for-Service Plans | 1 | 2016 | 69 | 0.030 |
Why?
|
| Water | 1 | 2018 | 309 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 738 | 0.030 |
Why?
|
| Genomics | 1 | 2019 | 370 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 319 | 0.030 |
Why?
|
| Transcriptome | 1 | 2018 | 388 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 718 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 358 | 0.020 |
Why?
|
| Agnosia | 1 | 2011 | 3 | 0.020 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2011 | 23 | 0.020 |
Why?
|
| Temporal Lobe | 1 | 2011 | 45 | 0.020 |
Why?
|
| Problem Solving | 1 | 2011 | 32 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2011 | 64 | 0.020 |
Why?
|
| Exercise | 1 | 2018 | 939 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 335 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2022 | 6630 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2011 | 391 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 5343 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1121 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 5656 | 0.020 |
Why?
|